In a recently accepted article published in Bioconjugate Chemistry, researchers from the University of Utah used CHPs in an antibody-conjugate to address Rheumatoid Arthritis(RA). In this paper, the authors used the Fab region from infliximab (an anti-TNFα therapy known as Remicade®) and conjugated this with CHPs. Numerous ELISA-like assays were used to verify the binding of the novel Fab-CHP was maintained, they tested the ability of Fab to bind TNFα a...